Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
28 oct. 2019 07h05 HE
|
Axsome Therapeutics, Inc.
Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more likely to prescribe AXS-07 over current and...
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
28 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Enrollment in MOMENTUM Phase 3 migraine trial of AXS-07 in patients with history of inadequate response nearly complete; on track for topline results in 4Q 2019 First patient dosed in new INTERCEPT...
Axsome Therapeutics to Provide Update on Continued Progress at the 2019 Cantor Global Healthcare Conference
02 oct. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD on track for readout of topline results in 4Q 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD on track for readout of topline results in 4Q...
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
05 sept. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response...
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
03 sept. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
20 août 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
08 août 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on track for readout of...
Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
30 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, August 8, 2019 at 8:00 AM Eastern Time NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
29 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Extends interest-only period and time to access additional funding NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company...
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
01 juil. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...